Abcam, ab89097, Anti-PRAME antibody

Size: 50µg
Mouse Polyclonal PRAME antibody. Carrier free. Suitable for WB and reacts with Human samples. Cited in 3 publications. Immunogen corresponding to Recombinant Full Length Protein corresponding to Human PRAME.
Key facts
Host species:Mouse,
Clonality:Polyclonal,
Isotype:IgG,
Carrier free:Yes,
Reacts with:Human,
Applications:WBSee reactivity dataSee the reactivity data table below for information on validated species and application combinations.,
Immunogen:Recombinant Full Length Protein corresponding to Human PRAME.P78395

Properties and Storage Information:
Form-Liquid, Purification technique-Affinity purification Protein A, Storage buffer-pH: 7.4Constituents: PBS, Shipped at conditions-Blue Ice, Appropriate short-term storage conditions-+4°C, Appropriate long-term storage conditions--20°C, Aliquoting information-Upon delivery aliquot, Storage information-Avoid freeze / thaw cycle

Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
PRAME also known as Preferentially Expressed Antigen in Melanoma is a protein typically weighing around 50 kDa. It is found mostly in testis tissue but also appears in several types of tumors including melanoma and some leukemias. PRAME does not show significant expression in most normal tissues making it a potential target for cancer therapies. Immunohistochemistry (IHC) techniques such as PRAME IHC and PRAME staining often use monoclonal antibodies like mAb EPR20330 to detect PRAME protein presence in various samples.
Biological function summary
PRAME acts as a repressor of retinoic acid signaling a process important for cell differentiation and growth. It does not directly form part of a complex but interacts with components involved in retinoic acid pathways. By binding to retinoic acid receptor complexes PRAME prevents activation of genes involved in cell cycle arrest and apoptosis contributing to unchecked cellular proliferation seen in certain cancers.
Pathways
PRAME participates in the retinoic acid and various oncogenic signaling processes. It influences the retinoic acid pathway by interfering with the retinoic acid receptor (RAR) signaling. This interference with key proteins like RAR disrupts the normal regulatory processes that typically inhibit cancer progression. PRAME's modulation of these pathways highlights its role in promoting tumor growth and survival.
PRAME has significant relevance to cancer particularly melanoma. It is often used as a biomarker for melanoma identification due to its overexpression in such tumors. Additionally PRAME's connection to acute myeloid leukemia (AML) emerges from its ability to act similarly in diverse malignant cells. In these diseases the overexpression of PRAME interferes with normal differentiation processes and allows for sustained proliferation of malignant cells suggesting its potential role as a therapeutic target or diagnostic marker in oncology.